There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Eli Lilly's 'Godzilla' weight loss drug retatrutide could offer more than just weight loss. The experimental drug, a once-weekly injection, has shown promising results in easing chronic knee pain among people with obesity and knee osteoarthritis in two Phase 3 clinical trials.

The findings, published in the New England Journal of Medicine (NEJM), suggest that the drug could address obesity and painful knee osteoarthritis, two interconnected health concerns. Participants receiving retatrutide experienced significant improvements in knee pain than those who received a placebo.

The findings are noteworthy as excess bodyweight can aggravate knee osteoarthritis more which can make everyday activities, including walking, climbing stairs and exercising, difficult.

What Is Retatrutide And How Does It Work?

Also read: Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric Symptoms

Retatrutide is a once-weekly injectable medication which belongs to a newer class of weight-loss drugs known as triple-hormone receptor agonists.

Unlike semaglutide (which targets GLP-1 receptors) and tirzepatide (which targets GLP-1 and GIP receptors), retatrutide activates three hormone receptors:

- GLP-1 (glucagon-like peptide-1): Helps regulate appetite, slow stomach emptying and control blood glucose levels.

- GIP (glucose-dependent insulinotropic polypeptide): Helps regulate insulin production and metabolic regulation.

- Glucagon: Plays a role in energy metabolism and can increase energy expenditure.

By targeting all three, retatrutide helps regulate appetite, food intake and energy metabolism, resulting in substantial weight loss and management of obesity-related illnesses.

Researchers wanted to investigate whether this amount of weight reduction could also help people experiencing chronic knee pain linked with osteoarthritis.

Findings From Two Clinical Trials

The findings come from two Phase 3 clinical trials, TRIUMPH-4 and TRIUMPH-1-OA, which enrolled 1,019 participants.

Both trials included overweight or obese adults with knee osteoarthritis. Participants did not have diabetes and were randomly assigned to receive different doses of retatrutide or a placebo.

1. TRIUMPH-4 trial

The trial included 445 participants who received either 9 mg or 12 mg of retatrutide or a placebo over 68 weeks.

- Participants receiving 9 mg of retatrutide experienced a 3.96-point reduction in their WOMAC pain score.

- Those receiving 12 mg experienced a 3.74-point reduction.

- The placebo group experienced a 2.12-point reduction.

Participants also experienced substantial weight loss. Those receiving 9 mg lost an average of 20% of their body weight, while the 12 mg group lost 23.7%. The placebo group lost 4.6%.

Also read: Not Everyone With Obesity Is Unhealthy: New Study Challenges BMI

2. TRIUMPH-1-OA trial

This trial enrolled 574 participants who received 4 mg, 9 mg or 12 mg of retatrutide or a placebo over 80 weeks. The results showed:

- The 4 mg group experienced a 3.22-point reduction in knee pain scores.

- The 9 mg group experienced a 3.48-point reduction.

- The 12 mg group experienced a 3.64-point reduction.

- The placebo group experienced a 1.87-point reduction.

Weight loss ranged from 17.5% to 24.8% across the three retatrutide groups, compared to 4.3% in the placebo group.

One encouraging finding emerged from the trials. Approximately 63% to 70% of participants receiving retatrutide experienced at least a 50% reduction in knee pain. This was compared to 38% of participants receiving a placebo.

Improvements in physical function were also observed, with approximately 64% of participants in the retatrutide groups experiencing at least a 50% improvement, compared to 33.1% in the placebo group.

Also read: Stopping Ozempic or Wegovy May Double Your Risk Of Heart Attack, Death

Side Effects Of Retatrutide

Despite the promising findings, researchers also identified safety concerns at higher doses of retatrutide. The most common adverse events were gastrointestinal problems, including nausea, diarrhoea and constipation. These symptoms were generally mild to moderate and occurred more frequently when dose was increased.

Another reported side effect was dysesthesia, an abnormal sensation of the skin that can include tingling, burning or unusual sensitivity.

In TRIUMPH-4, serious adverse events affected approximately 10% to 11% of participants receiving 9 mg or 12 mg of retatrutide, compared to 2% in the placebo group.

Furthermore, approximately 15% to 18% of participants receiving the highest dose discontinued treatment because of adverse events.

Weight Loss & Knee Health

Osteoarthritis is a degenerative joint condition in which the cartilage cushioning the ends of bones breaks down. This can cause pain, stiffness, swelling and difficulty in movement. Excess body weight can worsen the condition due to increased mechanical pressure on the knees and inflammation related to obesity.

While the findings offer hope for people living with chronic knee pain, researchers caution against interpreting pain relief as evidence that the drug can reverse osteoarthritis. Additionally, people who required knee replacement were excluded from the trials.

Regaining weight is one of common effects of stopping GLP-1 treatment for obesity. But apart from this, users have reported unusual side effects like hair fall, vision loss and even psychiatric symptoms.

According to two case reports published in the Primary Care Companion for CNS Disorders, stopping GLP-1 weight-loss drugs may ensue serious psychiatric symptoms in some patients like hallucinations, paranoia, mania and severe depression.

The reports describe two men who developed acute psychiatric symptoms after abruptly discontinuing tirzepatide, sold under the brand names Mounjaro and Zepbound. Both patients needed hospitalisation and psychiatric treatment.

The latest findings raise questions about the possible psychiatric effects of stopping GLP-1 medicines on the brain.

What Happened To The Two Patients?

Also read: Semaglutide May Lower Fetal Oxygen Levels During Pregnancy, Sheep Study Finds

The first case involved a 61-year-old man with a history of depression who stopped taking tirzepatide in August 2025 because of nausea.

Around two months later, he was hospitalised with worsening confusion and erratic behaviour. He experienced paranoia, auditory and visual hallucinations, and Cotard's delusion, a rare condition in which a person believes they are dead or no longer exist.

Medical investigations, including brain imaging, an electroencephalogram and tests of cerebrospinal fluid, did not identify a clear explanation for his symptoms. He received antipsychotic medication along with his existing antidepressant treatment.

Although his psychotic symptoms initially improved, he was readmitted weeks later with severe depression and catatonic features, a condition involving symptoms like reduced movement, unresponsiveness and difficulty communicating. He subsequently required electroconvulsive therapy.

The second case involved a 52-year-old man with a history of anxiety who abruptly stopped tirzepatide in September 2025 after losing approximately 100 pounds (45 kg) over six months.

About a month later, he developed significant mood and behavioural changes, including irritability, impulsivity, grandiosity and rapid, disorganised speech. Doctors diagnosed a manic episode. He was treated with an antipsychotic and transferred for psychiatric care.

Can Stopping GLP-1 Drugs Affect Mental Health?

Also read: Stopping Ozempic or Wegovy May Double Your Risk Of Heart Attack, Death

GLP-1 receptors are found not only in the digestive system but also in the brain, including regions involved in appetite, reward processing and mood regulation.

GLP-1 medicines influence these regions, which may partly explain why researchers are investigating their effects on mental health.

The authors of the case reports suggest that abruptly stopping the medication could contribute to sudden changes in mood or behaviour in certain vulnerable individuals. They also point towards dopamine signalling and neuroinflammatory processes.

However, researchers could not establish that withdrawal from tirzepatide was responsible for the psychiatric symptoms.

Both patients had pre-existing mental health conditions, which may have contributed to their symptoms. The second patient also had low vitamin B12 levels and increased marijuana use before developing symptoms.

The authors described the psychiatric symptoms after discontinuation of medication as “an underrecognized clinical phenomenon” and called for further research.

GLP-1 Drugs & Psychiatric Symptoms

The case reports do not mean that GLP-1 medicines cause psychosis, mania or other psychiatric disorders when stopped.

In January 2026, the US Food and Drug Administration (FDA) said its review of 91 clinical trials involving more than 107,000 participants found no increased risk of suicidal thoughts or behaviour with GLP-1 medicines.

It also found no increased risk of other psychiatric adverse events, including anxiety, depression, irritability and psychosis, compared to placebo.

However, that assessment primarily examined risks associated with taking the medicines. It does not settle the question of whether abrupt discontinuation could be linked with psychiatric symptoms in a small, vulnerable group.

The findings, however, indicate that patients should not stop GLP-1 treatment without discussing it with their healthcare provider. People may discontinue these medicines because of side effects, cost, access problems or other reasons, but a clinician can help change treatment plans.

Anyone experiencing new symptoms like confusion, hallucinations, extreme mood changes, paranoia or unusual behaviour after stopping a GLP-1 medication should seek urgent medical intervention.

A new blood test may help identify microscopic precancerous changes linked to ovarian cancer before a tumour develops, according to a study published in Nature Medicine. Researchers found that the test could detect a molecular signal associated with an early precursor of high-grade serous ovarian cancer, one of the most common and aggressive forms of the disease.

The study, led by researchers at the Hoag Family Cancer Institute in California, identified elevated levels of an RNA molecule called Tu-Stroma in blood samples from women with a condition known as serous tubal intraepithelial carcinoma (STIC).

The findings could eventually help identify women at increased risk of developing ovarian cancer, especially those with inherited genetic mutations.

What Is STIC And How Is It Linked To Ovarian Cancer?

High-grade serous ovarian cancer mostly originates in the fallopian tubes rather than directly in the ovaries. It may begin with microscopic changes in the cells lining the fallopian tubes, known as serous tubal intraepithelial carcinoma or STIC.

These lesions are precancerous, which means they are not invasive cancer but can lead to the development of high-grade serous ovarian cancer.

STIC is difficult to detect because the abnormal cells are microscopic and cannot be identified through routine imaging. They are often discovered incidentally when women undergo surgery to remove their fallopian tubes or ovaries.

Also read: Can AI End Cancer And Alzheimer’s? Anthropic CEO Dario Amodei Predicts ‘Age Of Miracles’ Within A Decade

How Does The New Blood Test Work?

The researchers found that women with STIC had elevated levels of Tu-Stroma, an RNA molecule related to interactions between abnormal cells and surrounding healthy tissue.

The molecule is linked to a process in which cancer cells weaken neighbouring healthy cells, creating an environment that allows abnormal cells to thrive.

By measuring Tu-Stroma in blood samples, researchers investigated whether this molecular signal could identify STIC before invasive cancer develops.

In a separate validation group, the test detected STIC in 92.3% of women who had the precancerous condition and correctly identified 98.2% of healthy women.

Researchers also modelled how the test might perform in a population of women with inherited risk factors for ovarian cancer. They estimated that approximately 72% of positive results would be accurate, while a negative result would be correct nearly 100% of the time.

Also read: Why Lobular Breast Cancer Can Be Difficult To Detect On A Mammogram?

Could The Test Help Women With BRCA1 And BRCA2 Mutations?

The findings may be relevant to women carrying inherited mutations in the BRCA1 and BRCA2 genes, which increase the risk of ovarian and breast cancers significantly.

Women with these mutations may be advised to consider surgery to remove of their fallopian tubes and ovaries. While this can reduce ovarian cancer risk, it also has consequences like including the loss of fertility and the possibility of early menopause.

Dr Esha Madan, co-author of the study and a researcher at Hoag Family Cancer Institute, said, “For women at high risk, this could transform how we approach prevention.”

She added, “Today, decisions about preventive surgery are largely guided by inherited risk, without knowing whether precancerous lesions are actually present. Our discovery could eventually provide that missing biological information.”

Also read: National Cancer Awareness Day: Diagnosed With Cancer In Your 20s Or 30s? What To Know About Fertility

Can This Blood Test Be Used For Ovarian Cancer Screening?

The study analysed previously collected blood samples from women whose diagnoses were already known. It did not test the blood marker prospectively in a large population of women undergoing routine screening.

The test performed well in samples from people with confirmed conditions and may not achieve the same accuracy in the general population.

Researchers are now planning prospective studies involving women with and without inherited risk factors. These studies will assess whether Tu-Stroma can identify precancerous changes before they progress and whether the results can shape clinical decisions.

Dr Rajan Gogna, who led the research, said, “We asked a fundamentally different question: What if we could identify the earliest molecular warning signs before invasive cancer even develops?”

The discovery offers a new direction for ovarian cancer detection, shifting the focus from finding an existing tumour to identifying biological changes that may precede it.